ABSTRACT
INTRODUCTION
As many as 65-75% of the estimated 3.5 million hepatitis C virus (HCV)-infected Americans are unaware of their infection status and have not received necessary care and treatment (1, 2) , and remain at high risk for progression to cirrhosis (3), liver failure, and hepatocellular carcinoma (2, (4) (5) (6) . Although rates of new HCV infections have declined since a peak in the 1990s (7) , overall prevalence has increased as patients discover their infection status. Given that individuals born between 1945 and 1965 represent roughly 75% of all US HCV cases, epidemiologists have anticipated a rapid upsurge of HCV-related liver disease and cirrhosis as this birth cohort ages (8) . Moreover, although HCV disproportionately affects men and African Americans (9) , changes in rates of these complications in these demographics have not been well-studied.
This rising burden of HCV-related complications is now being realized. A recent study of predominantly male US veterans (N>47,000) showed that the prevalence of cirrhosis increased from 9% in 1996 to 18.5% in 2006; decompensated cirrhosis increased from 5% to 11% over this same period(10). Similarly, a recent general population study using NHANES data found that HCV patients demonstrated increasing prevalence of cirrhosis, from 6.6% (in 1988-1994 ) to 17.0% (2007) (2008) (2009) (2010) (2011) (2012) (11) . This latter study was limited to a small sample (n=725). We sought to determine how the actual trends of cirrhosis and other
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complications have changed over the past decade, and whether race, sex and age impact these trends.
The Chronic Hepatitis Cohort Study (CHeCS) includes over 11,000 HCV patients receiving care at one of four large health systems. Because CHeCS comprises a geographically-and racially-diverse sample of patients receiving routine clinical care, it is broadly generalizable to HCV patients throughout the US (12) . We applied join-point modeling to comprehensive medical record data to investigate the dynamics of trends of cirrhosis, decompensated cirrhosis, and mortality among HCV patients from 2006 to 2015.
METHODS
CHeCS includes patients ≥18 years old who received services on or after January 1, 2006 at one of four health care systems-Henry Ford Health System; Geisinger Health System; Kaiser Permanente Northwest; and Kaiser Permanente Hawai'i. The study follows all guidelines of the US Department of Health and Human Services regarding the protection of human subjects; our protocol was approved and renewed annually by the Institutional Review Boards of Henry Ford Health System, Geisinger Health System; Kaiser Permanente Northwest; and Kaiser Permanente Hawai'i. Due to the de-identified nature of this observational study, requirements for written informed consent were waived. CHeCS methods have been described (12, 13) . Briefly, CHeCS patients are identified electronically using a combination of laboratory and ICD9-based criteria. Chronic HCV infection is confirmed through chart abstraction (12) . For each data collection cycle, a random sample of new patients is added to the cohort, while existing patients continue to be followed. In the present analysis, we examined annual prevalence of cirrhosis and decompensated cirrhosis, and incidence of all-cause mortality, for the 2006-2015 period.
Patients were included in the sample if they had been diagnosed prior to or during the given year, and their last encounter was during or after the given year. HBV/HCV co-infected patients were excluded; HIV/HCV co-infected patients were included in analyses.
Our classification of decompensated cirrhosis is based on a statistically rigorous classification and regression tree (CART) model that was validated against data from chart abstraction. This method classifies a cirrhotic patient to be decompensated cirrhosis if there was at least one of ICD9 codes for decompensation-related conditions, yielded validated AUROC of 92% and PPV of 85% (14) .
Accepted Article
Due to the observational nature of this study, availability of cirrhosis data varied. Roughly 20% of our sample had liver biopsy data; 60% had laboratory data for calculation of FIB4. To overcome this variation, we implemented a hierarchical classification algorithm to identify cirrhosis: 1) decompensated cirrhosis identified using the CART model; 2) "F4" liver biopsy;
3) FIB4>5.88; 4) presence of ICD9/10 diagnosis codes for cirrhosis in the medical record.
CHeCS has previously validated the use of the Fibrosis-4 (FIB4) serum-based biomarker in HCV patients; we found that a FIB4 score >5.88, calculated from routine laboratory results, accurately classifies cirrhosis (Metavir fibrosis stage F4; area under the receiver operator characteristic curve [AUROC]=85% and positive predictive value [PPV]=82%) (15) .
Decompensated cirrhosis was determined using a similar approach. Cirrhosis and decompensated cirrhosis were assumed to persist unless records indicated receipt of a liver transplant.
Statistical Analysis
Outcomes of interest included prevalence of cirrhosis and decompensated cirrhosis, as well as incidence of all-cause mortality (based on our work showing that liver-related mortality is under-reported in routine care settings (16) Summary statistics are presented as percentages (for categorical variables) and mean/standard deviations (for continuous variables) for each year. Chi-square tests were used to study time (year) effects on differences in patient characteristics across time.
To study the dynamics of longitudinal trends in the outcomes of interest, we adapted and extended a two-step join-point Poisson regression modeling approach (17) by fitting a series of straight lines on a log scale to the trend; each join-point represents a statistically significant (p<0.05) change in trend (i.e., slope of the line segment). For example, a single join-point splits the trend line into two line segments, whereas zero join-points indicates that the best fit to the trend consists of only a single line segment. In the first step, we identified the optimal join-point(s) using a nonlinear modeling approach. Next, multivariable analyses were performed based on the selected join-point(s) as well as potential stratification variables. Interactions were tested only for individual variables that were significant.
Variables were retained in the final model if estimated annual percentage changes (APCs) before and after the join-point were significant (p<0.05). We also evaluated whether the APC
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of each line segment differed from no change (APC=0). For each outcome of interest, we estimated adjusted APCs (aAPC) and 95% confidence intervals (CI), as well as adjusted prevalence rates by year or by age, race, or sex. Study sites were included in all analysis as the stratification variable.
We did not use age-standardized rates in the model to avoid masking the known birth-cohort effect in HCV patients born between 1945 and 1965(8) ; this is consistent with the approach used in a recent study of cirrhosis prevalence among US veterans (18) . However, age was included as a stratification variable. SAS Version 9.4 (SAS Institute Inc, Cary NC) was used for all analyses. Select patient demographics are presented in Table 1 . Notably, our cohort aged significantly over time. In 2006, only 14% of patients were >60 years old; this proportion increased to 49% by 2014. Likewise, the proportion of female patients increased from 40% to 43% over the same time period. The overall unadjusted prevalence of cirrhosis, decompensated cirrhosis, and incidence of all-cause mortality is illustrated in Figure 1 . There were three treatment eras during this ten year period, which are indicated in Figure 1 
RESULTS

We
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Prevalence of cirrhosis
Prevalence of cirrhosis (including decompensated cirrhosis) increased from 20.8% (in 2006)
to 27.6% (in 2015), with no join-point identified. The overall adjusted APCs (aAPC, adjusted for race, sex, and age category, Figure 2 ) was 1.2 (p<0.01). We did not find any interactions between time and covariates (age, sex or age), indicating that-although each factor independently impacted prevalence rates-their effect was consistent over time. Notably, both Black/ African American and AAPI patients demonstrated significantly higher prevalence of cirrhosis than White patients (p<0.01). Older patients (especially those ≥60) and men also demonstrated significantly higher prevalence than younger patients or women, respectively. Consistent with the overall results, increases in cirrhosis rates among these groups were consistent over time.
Prevalence of decompensated cirrhosis
The model for prevalence of decompensated cirrhosis also fitted to a straight line (no joinpoints) with APC of 1.5 (p<0.01), indicating that the increase from 9.3% (in 2006) to 10.4% (in 2015) was consistent across the study period. However, the multivariate analysis showed a significant interaction between age and time; this indicates that the trend (APC) varied across age groups. We found that higher prevalence and increasing trends were both confined to patients ≥60 (aAPC=1.5, p=0.023). Lower prevalence and declining trends were observed in patients 40-<50 and 50-<60 (aAPCs=-3.2 and -7.9, respectively; p<0.01 for both); no change was observed among patients <40 (Figure 3) . Men demonstrated higher prevalence of decompensated cirrhosis than women, while higher rates of decompensated cirrhosis were found in Black/ African American and AAPI patients than White patients (p<0.01).
Incidence of all-cause mortality
Overall incidence of all-cause mortality increased across the study period, from 1.8% (in 2006) to 2.9% (in 2015). However, this increase was confined almost entirely to the period prior to the 2010 join-point ( Figure 1, Table 2 ). APCs were 13.7 and -1.6 (p<0.01 and 0.28) before and after 2010, respectively; aAPCs were 9.6 and -5.2 (p<0.01 for both), indicating that there was a significant decrease in incidence of all-cause mortality after 2010. We observed that age, sex contributed independently to incidence of mortality (Figure 4 ), but trends remained consistent across time among groups. Older patients (especially those ≥60) and men again demonstrated the highest incidence of mortality (Figure 4 ). Despite higher rates of cirrhosis among Black/ African American and AAPI patients compared to White, there was no significant difference in mortality by race (p=0.13).
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DISCUSSION
Consistent with recent studies, we found a marked increase in cirrhosis prevalence from 2006 to 2015 in a diverse, non-veteran-based cohort of over 11,000 HCV patients.
Likewise, even though the overall rate of all-cause mortality roughly doubled from 2006 to 2010, incidence declined after 2010. Trends in prevalence of decompensated cirrhosis varied by age; although prevalence increased significantly in patients ≥ 60 years old, rates plateaued or declined among younger age groups.
Our observation of increasing prevalence of cirrhosis but decreasing rates of decompensated cirrhosis and all-cause mortality suggests that cirrhotic patients are living longer. This may be a result of more frequent antiviral treatment among cirrhotic patients (we observed an increase from 22% in 2006 to 53% in 2015), reducing the number of patients who progress to decompensated cirrhosis and death. Although there is some evidence that liver fibrosis may regress after SVR, we cannot adequately capture this regression. Being conservative, we considered cirrhosis to persist in the absence of a liver transplant, We found significant disparities in the prevalence of HCV-related complications across age, sex, and racial categories. HCV patients ≥60 years old had the highest prevalence of liverrelated complications and all-cause mortality; similar findings have been reported among US veterans (19) . Sex also independently influenced all outcomes (Figures 2-4 ), although to a lesser extent than age. Men had the highest prevalence of cirrhosis and decompensated cirrhosis, as well as incidence of mortality.
We observed that decompensated cirrhosis increased only 1 percentage point in 10 years, and only among patients in the oldest age group (≥60), despite larger increases in the prevalence of cirrhosis across all age groups. We speculate that this may be due to improvements in HCV treatment, particularly among patients with advanced fibrosis (6, 20) .
Although we observed an overall increase in the incidence of all cause-mortality (from 1.8% in 2006 to 2.9% in 2015), our analyses indicated that the rate of increase reversed after 2010; this may also be related to better HCV treatment options as well as improved survival in patients with late-stage liver disease (21, 22) .
Notably, Black/ African American patients in our cohort demonstrated the highest prevalence of cirrhosis, even after controlling for age. This finding is in contrast to studies that have found lower risk of cirrhosis among Black patients with HCV (23) (24) (25) . A number of previous studies have shown that Black/ African Americans were historically less likely to receive
Accepted Article
interferon-based HCV treatment (26) (27) (28) (29) ; our own recent study of the factors associated with DAA uptake has demonstrated the same pattern (30) . The higher prevalence of cirrhosis observed in this racial group may be related to differences in receipt of therapy or access to care. Future studies investigating the causes of these disparities are warranted.
Our study has several limitations. We used all-cause mortality instead of HCV-related mortality because a previous CHeCS analysis demonstrated that liver-related mortality is under-reported in routine-care settings (16) . Although our analysis is based on ongoing "dynamic" cohort accrual from health system populations, the cohort has aged significantly over time; patients ≥60 years made up only 15% of our 2006 cohort, but more than a half (53%) of the cohort in 2015. However, we tested for interactions between age and time trends. Likewise, we did not adjust for the effect of treatment or SVR on these trends because our analysis was designed to describe overall temporal changes HCV-related complications, rather than individual treatment effect on a patient's trajectory, which has been studied thoroughly for interferon-based treatment (6, 20) . It would not be appropriate to assess treatment effect in the present trend analysis, because HCV treatment-related factors, including eligibility for treatment/treatment uptake, treatment failure (especially for interferonbased treatment), treatment response (SVR) and the rate of SVR responses, are a function of the era of HCV treatment. Nevertheless treatment impact may be minimal in the present trend analysis given low HCV treatment uptake and SVR responses in this population.
Because our cohort consists of individuals with at least some contact with the health system, we are unable to estimate the prevalence of outcomes in HCV-positive individuals who remain undiagnosed or those without ongoing contact with a health care system. Such individuals are perhaps most at risk for poor outcomes. In addition, our study is based primarily upon health records data and may fail to capture factors that potentially affect clinical outcomes, such as disease duration or undiagnosed substance or alcohol abuse.
Our study is also limited generally to the era of interferon-based therapy through the introduction of triple therapy that included the initial protease inhibitors boceprevir and telaprevir.
In conclusion, although overall prevalence of cirrhosis increased by roughly 40% among HCV-infected patients in the US, all-cause mortality declined significantly in recent years.
Likewise, increasing prevalence of decompensated cirrhosis was confined to patients over 60. Accelerating uptake of highly effective direct-acting all-oral regimens may ultimately reverse the increase of liver-related complications in this population.
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